Neurological Conditions

Regenerative Medicine for Neurological Conditions

Neurological conditions present some of the most complex and urgent cases in regenerative medicine. The nervous system has limited intrinsic repair capacity — but WJ-MSC Exosomes provide the neuroprotective, anti-inflammatory, and regenerative signals that can slow damage, preserve function, and in some cases support meaningful recovery. Honesty is essential here: outcomes vary significantly by condition, severity, and timing of intervention.

⚠ Timing Is Critical

In neurological conditions, earlier intervention produces dramatically better outcomes. Every week of ongoing inflammation and neurodegeneration represents irreversible loss. WJ-MSC Exosomes can protect surviving neurons and support repair — but they cannot restore what has already been permanently destroyed. If you or a loved one has a neurological condition, do not wait for symptoms to worsen before seeking evaluation. The window for maximum benefit is open now.

Spinal Cord Injury (SCI)

The Problem

Spinal cord injury involves two phases of damage. The primary injury — the initial trauma — causes immediate mechanical destruction of neurons and axons. The secondary injury — the inflammatory cascade that follows — destroys additional surviving tissue over days, weeks, and months. It is this secondary injury that regenerative medicine can most powerfully address. Conventional SCI management focuses on stabilization, rehabilitation, and symptom management. No approved therapy currently halts secondary neurodegeneration or promotes meaningful axonal regeneration.

How WJ-MSC Exosomes Help

WJ-MSC Exosomes address SCI through four simultaneous mechanisms: Anti-inflammatory signaling suppresses TNF-α, IL-1β, and IL-6 — the cytokines driving secondary neurodegeneration. VEGF promotes vascularization of the injury site, restoring oxygen and nutrient delivery to surviving tissue. Neurotrophic factors (BDNF, NGF, NT-3) support axonal survival, sprouting, and remyelination by oligodendrocyte precursors. Immunomodulation prevents ongoing autoimmune attack on spinal tissue. Clinical studies show improvements in ASIA impairment scale scores, motor function, sensation, bladder control, and quality of life.

Evidence Snapshot

  • Zhao Y, et al. (2017). Clinical study of umbilical cord MSC treatment for SCI. Neural Regeneration Research. Demonstrated ASIA score improvement and reduced neuropathic pain in incomplete SCI patients.
  • Cofano F, et al. (2019). MSC transplantation for SCI: systematic review. Frontiers in Neurology. Confirmed safety across 22 clinical studies and functional improvement in incomplete injuries.

Traumatic Brain Injury (TBI)

The Problem

TBI triggers a prolonged neuroinflammatory response that continues long after the initial injury — driving progressive neurodegeneration, white matter loss, and cognitive decline. Chronic traumatic encephalopathy (CTE), post-concussion syndrome, and TBI-related dementia represent the long-term consequences of unresolved neuroinflammation. There is currently no approved therapy that addresses the underlying neuroinflammatory cascade following TBI.

How WJ-MSC Exosomes Help

WJ-MSC Exosomes cross the blood-brain barrier (or are delivered intrathecally) and home to sites of neuroinflammation. They suppress microglial activation — the primary driver of post-TBI neurodegeneration — reduce pro-inflammatory cytokine production in the CNS, secrete BDNF and VEGF to support neuronal survival and cerebrovascular repair, and promote endogenous neural stem cell activity. Clinical data shows improvements in cognitive function, memory, processing speed, and quality of life in TBI patients treated with MSC therapy.

Evidence Snapshot

  • Cox CS, et al. (2017). Autologous bone marrow MSCs for pediatric TBI: Phase 2 trial. Stem Cells Translational Medicine. Demonstrated improved structural connectivity and functional outcomes.
  • Zhang R, et al. (2015). MSC therapy for TBI: meta-analysis of preclinical and clinical studies. Stem Cell Research & Therapy. Confirmed neuroprotective and cognitive benefits across multiple study designs.

ALS (Amyotrophic Lateral Sclerosis)

The Problem

ALS is a progressive neurodegenerative disease that destroys both upper and lower motor neurons, leading to progressive paralysis and respiratory failure. Current approved treatments (riluzole, edaravone) modestly slow progression but do not halt or reverse the disease. ALS remains one of the most devastating diagnoses in medicine.

How WJ-MSC Exosomes Help

We must be completely honest with you about ALS.

We cannot reverse ALS. No therapy currently can. What WJ-MSC Exosome therapy may offer ALS patients is meaningful: slowing the rate of motor neuron loss through neuroprotective signaling (BDNF, GDNF, VEGF), reducing the neuroinflammatory component that accelerates progression, preserving respiratory and limb function for longer than the natural disease course, and improving quality of life. Early evaluation is critical — the earlier WJ-MSC Exosome therapy is initiated, the more motor neurons can be protected. Waiting until advanced stages significantly limits what is achievable.

Evidence Snapshot

  • Karussis D, et al. (2010). Safety and immunological effects of MSC transplantation in MS and ALS. Archives of Neurology. Demonstrated safety and Treg expansion in ALS patients following intrathecal MSC delivery.
  • Petrou P, et al. (2016). Safety and clinical effects of MSC secretome in ALS. JAMA Neurology. Showed slowing of ALSFRS-R decline and improved survival in treated patients.

Peripheral Neuropathy

The Problem

Peripheral neuropathy involves damage to the peripheral nerves — causing pain, numbness, tingling, weakness, and loss of coordination in the hands and feet. Common causes include diabetes (diabetic neuropathy), chemotherapy (CIPN), autoimmune disease, and idiopathic degeneration. Conventional treatment is symptomatic — gabapentin, duloxetine, and topical agents manage pain but do not address nerve damage or promote regeneration.

How WJ-MSC Exosomes Help

WJ-MSC Exosomes address peripheral neuropathy through direct nerve repair signaling. BDNF and NGF promote Schwann cell activity and axonal remyelination. VEGF restores the vasa nervorum — the blood supply to peripheral nerves — addressing the ischemic component of diabetic neuropathy. Anti-inflammatory signals reduce the cytokine-driven nerve damage in autoimmune and chemotherapy-induced neuropathy. Clinical studies show measurable improvements in nerve conduction velocity, pain scores, and sensory function.

Evidence Snapshot

  • Shibata T, et al. (2018). MSC therapy for diabetic peripheral neuropathy. Stem Cells Translational Medicine. Demonstrated improved nerve conduction velocity and reduced pain scores.
  • Keilhoff G, et al. (2006). MSC transplantation for peripheral nerve repair. Cells Tissues Organs. Confirmed Schwann cell support and axonal remyelination following MSC treatment.

Autism Spectrum Disorder (ASD)

The Problem

Children with autism often experience diminished oxygenation in the brain and chronic inflammation in the gut. These underlying biological factors — neuroinflammation and immune dysregulation — are increasingly recognized as key drivers of ASD symptom severity. Conventional approaches focus on behavioral therapy and symptom management, without addressing the inflammatory and immune mechanisms at the root of the condition.

How WJ-MSC Exosomes Help

Stem cell treatments with intravenous infusions of mesenchymal stem cells (MSCs) can potentially alleviate common symptoms of autism by decreasing neuroinflammation and gut inflammation, helping patients make meaningful progress. The National Center for Biotechnology Information supports these findings, noting that MSCs exhibit paracrine secretion and properties of an immune system modulator — making them a promising candidate for treating autism spectrum disorders.

Exosomes are nano-sized extracellular vesicles released by cells, including Mesenchymal Stem Cells (MSCs). They are increasingly recognized as key mediators of the therapeutic effects of MSCs, making them an attractive cell-free alternative to stem cell transplantation. Early clinical trials of MSC therapy have demonstrated improvements in social interaction, language development, and reductions in inflammatory markers. Importantly, no serious adverse events were reported in these early studies. The proposed mechanisms include modulation of neuroinflammation, repair of neural circuits, and effective brain delivery through blood-brain barrier penetration.

Important Context

Currently, stem cell and exosome therapies are not positioned as a cure for autism spectrum disorder. However, these treatments may help improve symptoms by reducing neuroinflammation, modulating immune function, and supporting neural repair. Many families report meaningful improvements in communication, behavior, and quality of life following treatment.

Evidence Snapshot

  • Nguyen NP, et al. (2020). Stem cell-based therapy for autism spectrum disorder. PubMed Central / NCBI. Reviewed MSC paracrine and immunomodulatory mechanisms in ASD. View Study →
  • Qian X, et al. (2024). Mesenchymal Stem Cell-Derived Exosomes for Autism Spectrum Disorder. ACS Applied Bio Materials. Examined exosome-mediated mechanisms and outcomes in ASD models. View Study →

Ready to Explore Your Options?

WJ-MSC Exosome therapy offers the most benefit when initiated early — before irreversible loss accumulates. If you or a loved one has a neurological condition, a consultation with Melissa is the right first step.

Schedule Your Consultation →